Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Direxion Debuts New Single-Stock ETFs for Eli Lilly & Palo Alto

BY | ETF Database
03/26/2025 | 72 VIEWS
  • Related Symbols
  • TMF
On Wednesday, Direxion expanded its suite of leveraged and inverse ETF products with the launch of four new funds. Each of the new Direxion ETFs offers leveraged or inverse exposure to a single stock’s daily price performance. All four of the funds have net expense ratios of 97 basis points.  Two of the new funds look at the daily stock performance for Eli Lily (LLY). The Direxion Daily Bull 2X Shares (ELIL) looks to generate 2x of LLY’s daily returns. Meanwhile, the Direxion Daily LLY Bear 1X Shares (ELIS) offers -100% of the stock’s daily price performance.  Investors focused on the cybersecurity sector may find the other two Direxion ETFs interesting. The Direxion Daily PANW Bull 2X Shares (PALU) offers a bullish take on Palo Alto Networks (PANW) daily stock movements. Alternatively, the Direxion Daily PANW Bear 1X Share (PALD) instead opts for inverse exposure.  These leveraged and inverse ETFs use swap agreements and options to generate their daily exposure to a single stock. Generally speaking, all four funds will attempt to execute on their investment strategies regardless of how the individual stocks or greater market are performing. Advantages of ExposureBoth cybersecurity and healthcare have proven to be sectors that investors are interested in gaining more exposure to. As such, these funds can serve as efficient tools for gaining short-term access to concentrated stock performance.  “We see headlines that are impacting either the pharmaceutical or cybersecurity sectors, whether it be changes in the government stance around healthcare, or changes in tariffs that are impacting AI or cybersecurity,” said Douglas Yones, CEO of Direxion. “Eli Lilly and Palo Alto Networks are the types of companies that move around quite a bit, the ones that our traders look to us to provide leveraged and inverse strategies on.” See More: Douglas Yones on Direxion’s Lineup & ETF Education at Exchange Given the daily nature of their investment objectives, these funds can offer both high reward and high risk. As such, investors and advisors may want to research the advantages of leveraged and inverse funds before pursuing direct investment.  These new funds join Direxion’s ever-growing network of competitive leveraged & inverse funds. For instance, one of the largest Direxion ETFs, the Direxion Daily 20+ Year Treasury Bull 3X Shares (TMF C+), has well over $5 billion in assets under management. For more news, information, and analysis, visit the Leveraged & Inverse Channel.

More Commentary

Active Value ETF TVAL Adds a Quarter Billion in 1 Month
BY | ETF Database
5:21 am ET 03/31/25 | 52 VIEWS
Gold's Rally Continues to Tee Up Opportunities for Miners
BY | ETF Database
10:26 am ET 03/31/25 | 20 VIEWS
Active ETF Specialist T. Rowe Price Adds 2 New Active Funds
BY | ETF Database
03/28/2025 | 137 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.